BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.19), $0.06 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $86.74 million versus the consensus estimate of $86.06 million.

Financial Outlook for 2023

The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million, versus the consensus of $327.3 Million. The company continues to be disciplined in its approach to capital allocation and is reducing its outlook for operating expenses for full year 2023, not including non-cash stock compensation, to between $365 million and $375 million, reflecting an expected decline from 2022 operating expenses.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.